AFT Pharmaceuticals Limited (AFT.NZ)
NZD 2.8
(0.0%)
NZD 2.8
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 20.14 Million NZD | -39.49% |
| 2023 | 33.3 Million NZD | 2.25% |
| 2022 | 32.56 Million NZD | -16.51% |
| 2021 | 39 Million NZD | -5.05% |
| 2020 | 41.08 Million NZD | 17.94% |
| 2019 | 34.83 Million NZD | 45.85% |
| 2018 | 23.88 Million NZD | 220.76% |
| 2017 | 7.44 Million NZD | 268.88% |
| 2016 | -4.4 Million NZD | -127.49% |
| 2015 | 16.03 Million NZD | 34.84% |
| 2014 | 11.89 Million NZD | 3.8% |
| 2013 | 11.45 Million NZD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 20.14 Million NZD | -39.49% |
| 2024 Q3 | 19.35 Million NZD | -44.36% |
| 2024 Q1 | 34.03 Million NZD | 2.2% |
| 2024 Q4 | 20.14 Million NZD | 4.11% |
| 2024 Q2 | 34.78 Million NZD | 2.2% |
| 2023 Q3 | 32.72 Million NZD | 0.67% |
| 2023 Q4 | 33.3 Million NZD | 1.74% |
| 2023 FY | 33.3 Million NZD | 2.25% |
| 2023 Q1 | 31.99 Million NZD | -1.75% |
| 2023 Q2 | 32.51 Million NZD | 1.61% |
| 2022 Q1 | 35.58 Million NZD | -8.78% |
| 2022 Q4 | 32.56 Million NZD | 1.69% |
| 2022 Q3 | 32.02 Million NZD | -11.43% |
| 2022 FY | 32.56 Million NZD | -16.51% |
| 2022 Q2 | 36.16 Million NZD | 1.62% |
| 2021 Q2 | 38.32 Million NZD | 1.58% |
| 2021 Q1 | 37.72 Million NZD | -8.17% |
| 2021 Q3 | 38.39 Million NZD | 0.19% |
| 2021 Q4 | 39 Million NZD | 1.6% |
| 2021 FY | 39 Million NZD | -5.05% |
| 2020 Q4 | 41.08 Million NZD | 1.25% |
| 2020 Q2 | 42.66 Million NZD | 1.27% |
| 2020 Q1 | 42.13 Million NZD | 20.95% |
| 2020 FY | 41.08 Million NZD | 17.94% |
| 2020 Q3 | 40.57 Million NZD | -4.9% |
| 2019 Q4 | 34.83 Million NZD | 0.0% |
| 2019 FY | 34.83 Million NZD | 45.85% |
| 2019 Q3 | 34.83 Million NZD | 0.86% |
| 2019 Q2 | 34.53 Million NZD | 0.0% |
| 2019 Q1 | 34.53 Million NZD | 44.61% |
| 2018 Q1 | 16.04 Million NZD | 115.51% |
| 2018 Q4 | 23.88 Million NZD | 0.0% |
| 2018 Q3 | 23.88 Million NZD | 48.84% |
| 2018 Q2 | 16.04 Million NZD | 0.0% |
| 2018 FY | 23.88 Million NZD | 220.76% |
| 2017 FY | 7.44 Million NZD | 268.88% |
| 2017 Q2 | 5.98 Million NZD | 0.0% |
| 2017 Q1 | 5.98 Million NZD | 222.29% |
| 2017 Q3 | 7.52 Million NZD | 25.66% |
| 2017 Q4 | 7.44 Million NZD | -1.0% |
| 2016 Q3 | -4.89 Million NZD | 51.14% |
| 2016 Q2 | -10.01 Million NZD | -168.11% |
| 2016 FY | -4.4 Million NZD | -127.49% |
| 2016 Q4 | -4.89 Million NZD | 0.0% |
| 2016 Q1 | 14.7 Million NZD | -8.32% |
| 2015 Q4 | 16.03 Million NZD | 0.0% |
| 2015 Q1 | 1.24 Million NZD | 0.0% |
| 2015 Q3 | 16.03 Million NZD | 0.0% |
| 2015 FY | 16.03 Million NZD | 34.84% |
| 2014 FY | 11.89 Million NZD | 3.8% |
| 2013 FY | 11.45 Million NZD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Greenfern Industries Limited | 668.43 Thousand NZD | -2914.49% |
| Rua Bioscience Limited | -747.35 Thousand NZD | 2796.189% |